샘플 요청 목록

 카트 문의
시장보고서
상품코드
2156162

암 진단 시장

Cancer Diagnostics
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 488 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,891,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 14,993,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,673,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 암 진단 시장은 2032년까지 1,554억 달러에 달할 전망

2025년 1,114억 달러로 추산되는 세계 암 진단 시장은 2032년까지 1,554억 달러에 달할 것으로 예상되며, 2025-2032년의 분석 기간 동안 연평균 성장률(CAGR) 4.9%로 성장할 것으로 전망됩니다. 본 보고서에서 분석 대상으로 삼고 있는 부문 중 하나인 ‘장비’는 연평균 성장률(CAGR) 6.1%를 기록하며, 분석 기간이 끝날 때까지 689억 달러에 달할 것으로 예측됩니다. ‘소모품’ 부문의 성장률은 분석 기간 동안 연평균 성장률(CAGR) 3.5%를 나타낼 것으로 추정됩니다.

미국 시장은 300억 달러로 추산되는 반면, 중국은 연평균 성장률(CAGR) 8.8%를 나타낼 것으로 예측됩니다.

2025년 미국의 암 진단 시장 규모는 300억 달러로 추산됩니다. 세계 2위의 경제 대국인 중국은 2025-2032년의 분석 기간 동안 연평균 성장률(CAGR) 8.8%를 기록하며, 2032년까지 시장 규모가 351억 달러에 달할 것으로 예측됩니다. 그 밖의 주목할 만한 지역 시장으로는 일본과 캐나다가 꼽히며, 분석 기간 동안 각각 연평균 성장률(CAGR) 1.9% 및 3.8%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 연평균 성장률(CAGR) 약 2.9%를 나타낼 것으로 예측됩니다.

세계 암 진단 시장 - 주요 동향 및 촉진요인 개요

왜 암 진단은 의료 혁신의 최전선에 있는 것일까？

암 진단은 의료 분야에서 매우 중요한 영역으로, 암의 조기 발견, 진단, 경과 관찰에 필수적인 수단을 제공함으로써 환자의 예후를 크게 개선합니다. 암을 정확하고 조기에 진단할 수 있다는 것은 치료 성공률과 생존율에 지대한 차이를 가져옵니다. 오랜 세월에 걸쳐 암 진단은 기본적인 영상 진단 기술에서 고도로 정교한 분자·유전자 검사로 진화하여, 특정 암 유형, 그 진행 상황 및 치료 방침에 영향을 미칠 수 있는 유전자 변이를 식별할 수 있게 되었습니다. 생검, 혈액 검사, 영상 진단법(MRI 및 CT 스캔 등), 유전체 프로파일링과 같은 다양한 진단 기술의 통합을 통해 임상의는 환자의 암에 대해 종합적으로 파악할 수 있게 되었습니다. 또한, 액체 생검 및 차세대 염기서열 분석(NGS)의 발전으로 인해 조기 암의 검출 및 경과 관찰 방법이 크게 변화했습니다. 이 분야가 발전함에 따라 암 진단은 더욱 정밀하고 개인 맞춤형으로 변모하여, 치료 전략 수립 및 환자 생존율 향상에서 매우 중요한 역할을 수행하고 있습니다.

기술 혁신은 암 진단을 어떻게 발전시키고 있는가?

급속한 기술 혁신은 암 진단의 양상을 근본적으로 변화시키고 있으며, 더 정확하고 조기 검출을 가능하게 하는 새로운 도구와 조사 기법을 탄생시키고 있습니다. 가장 중요한 발전 중 하나는 암의 증식을 촉진하는 유전자 변이에 대한 인사이트를 제공하는 유전체 진단 및 분자진단의 부상입니다. 차세대 염기서열 분석(NGS)을 통해 환자의 유전자 프로파일을 종합적으로 분석할 수 있게 되었으며, 이를 통해 임상의는 개별 암의 특성에 맞추어 치료법을 조정할 수 있게 되어 맞춤형 의료가 현실이 되었습니다. 또 다른 최첨단 기술인 액체 생검은 간단한 혈액 검사를 통해 암을 검출할 수 있게 하여, 기존의 조직 생검을 대체할 수 있는 비침습적이고 신속한 대안을 제공합니다. 이 기술은 조기 발견뿐만 아니라 암의 진행 상황 및 치료 효과 모니터링에도 유용합니다. 인공지능(AI)과 머신러닝 또한 영상 진단 기술의 향상, 암 검진 정확도 향상, 그리고 복잡한 데이터 세트의 분석을 전례 없는 속도로 가능하게 하는 등 큰 성과를 거두고 있습니다. 이러한 혁신을 통해 진단 과정이 효율화되고 조기 발견이 가능해졌으며, 보다 정확하고 개인 맞춤형 치료 접근법을 통해 환자의 예후 개선이 촉진되고 있습니다.

암 진단 분야의 새로운 동향과 과제는 무엇일까？

현재 암 진단 시장을 형성하고 있는 몇 가지 중요한 동향이 있으며, 각각이 암의 검출 및 관리 방식에 영향을 미치고 있습니다. 주요 동향 중 하나는 액체 생검이나 첨단 영상 진단 기술과 같은 비침습적 진단법에 대한 수요 증가입니다. 이러한 방법은 환자의 불편함을 최소화하고 결과가 나오기까지 걸리는 시간을 단축합니다. 환자와 의료진 모두가 더 안전하고 편리한 선택지를 추구하는 가운데, 이러한 저침습적 방법으로의 전환이 가속화되고 있습니다. 또 다른 동향은 암 검진이 생명을 구할 수 있다는 인식이 높아짐에 따라 조기 발견이 점점 더 중요시되고 있다는 점입니다. 유방암, 대장암, 폐암 등의 암 검진 프로그램이 확대되면서, 암을 가장 초기 단계에서 발견할 수 있는 진단 도구에 대한 수요가 높아지고 있습니다. 그러나 이 분야에는 몇 가지 과제도 존재합니다. 첨단 진단 기술의 복잡성과 비용은 특히 저·중소득 지역에서 그 보급의 장벽이 될 수 있습니다. 또한, 유전체 검사나 영상 진단을 통해 생성되는 방대한 양의 데이터에는 고도의 데이터 관리 및 분석 시스템이 필요하며, 이는 의료 종사자들에게 데이터 통합 및 해석 측면에서 과제가 되고 있습니다. 이러한 과제가 있음에도 불구하고, 맞춤형 의료와 조기 발견의 추세는 암 진단 분야의 혁신을 지속적으로 뒷받침하고 있습니다.

암 진단 시장의 확장을 뒷받침하고 있는 요인은 무엇일까？

암 진단 시장의 성장은 주로 기술 발전, 암 유병률 상승, 그리고 조기 발견과 맞춤형 치료에 대한 중요성 증대 등 몇 가지 요인에 의해 주도되고 있습니다. 주요 성장 요인 중 하나는 분자진단, 특히 차세대 염기서열 분석(NGS) 및 액체 생검 기술에 대한 수요의 급증입니다. 이러한 기술들은 암을 검출하기 위한 더 정확하고 비침습적인 대안을 제공합니다. 개인의 유전자 프로파일에 맞추어 치료 계획을 수립하는 맞춤형 의료의 확산 또한 특정 바이오마커나 변이를 식별할 수 있는 진단 도구에 대한 수요를 부추기고 있습니다. 또한, 고령화 및 생활 습관과 관련된 위험 요인 등으로 인해 세계적으로 암 발병률이 증가하고 있어, 암을 조기에 발견하고 환자의 예후를 개선할 수 있는 진단 솔루션에 대한 수요가 높아지고 있습니다. 정기적인 암 검진을 장려하는 정부의 이니셔티브와 의료 정책 또한, 특히 선진국 시장에서 진단 검사 수요를 뒷받침하고 있습니다. 시장 성장을 견인하는 또 다른 중요한 요인은 진단용 영상 진단 및 데이터 분석에 인공지능(AI)과 머신러닝을 통합함으로써 암 감지의 정확도와 속도가 향상되고 있다는 점입니다. 이러한 요인들에 더해 신흥 시장의 진단 역량이 지속적으로 확대됨에 따라, 향후 몇 년간암 진단 업계의 급속한 성장이 지속될 것으로 예측됩니다.

부문:

제공 내용(장비, 소모품, 서비스), 검사 유형(생검 검사, 기타 검사), 용도(유방암, 대장암, 자궁경부암, 폐암, 전립선암, 피부암, 혈액암, 기타 용도), 최종 용도(병원, 검사실, 기타 용도)

주요 기업

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Applied Image Inc.
  • AstraZeneca PLC
  • AutoGenomics, Inc.
  • Becton, Dickinson Company
  • Bayer AG
  • BioCorRx, Inc.
  • bioMeriux SA
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Pfizer, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

해당 분야의 전문가 관점을 바탕으로 합니다. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다 - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다-컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업 공시 정보, 연차 보고서, 기관지 및 기타 검증된 정보원에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다 - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다 - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 26.10.29

Global Cancer Diagnostics Market to Reach US$155.4 Billion by 2032

The global market for Cancer Diagnostics estimated at US$111.4 Billion in the year 2025, is expected to reach US$155.4 Billion by 2032, growing at a CAGR of 4.9% over the analysis period 2025-2032. Instruments Offering, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$68.9 Billion by the end of the analysis period. Growth in the Consumables Offering segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$30.0 Billion While China is Forecast to Grow at 8.8% CAGR

The Cancer Diagnostics market in the U.S. is estimated at US$30.0 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$35.1 Billion by the year 2032 trailing a CAGR of 8.8% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Cancer Diagnostics Market - Key Trends and Drivers Summarized

Why Is Cancer Diagnostics at the Forefront of Medical Innovation?

Cancer diagnostics is a critical field within healthcare, providing essential tools for the early detection, diagnosis, and monitoring of cancer, significantly improving patient outcomes. The ability to diagnose cancer accurately and at an early stage can make a tremendous difference in treatment success rates and survival. Over the years, cancer diagnostics has evolved from basic imaging techniques to highly sophisticated molecular and genetic testing, enabling the identification of specific cancer types, their progression, and genetic mutations that may influence treatment decisions. The integration of various diagnostic technologies, such as biopsy, blood tests, imaging modalities (like MRI and CT scans), and genomic profiling, provides clinicians with a comprehensive view of a patient’s cancer. Moreover, advancements in liquid biopsy and next-generation sequencing (NGS) have transformed how early-stage cancer is detected and monitored. As the field advances, cancer diagnostics is becoming more precise and personalized, playing a crucial role in shaping treatment strategies and improving patient survival rates.

How Are Technological Innovations Driving Cancer Diagnostics?

The rapid pace of technological innovation is profoundly reshaping the cancer diagnostics landscape, bringing forth new tools and methodologies that allow for more accurate and earlier detection. One of the most significant developments has been the rise of genomic and molecular diagnostics, which provide insights into the genetic mutations driving cancer growth. Next-generation sequencing (NGS) enables the comprehensive analysis of a patient’s genetic profile, helping clinicians tailor treatments to the individual’s unique cancer characteristics, making personalized medicine a reality. Liquid biopsy, another cutting-edge advancement, allows for the detection of cancer through a simple blood test, offering a less invasive and faster alternative to traditional tissue biopsies. This technology is not only useful for early detection but also for monitoring cancer progression and treatment efficacy. Artificial intelligence (AI) and machine learning are also making their mark by enhancing imaging technologies, improving the accuracy of cancer screening, and allowing for the interpretation of complex datasets at an unprecedented speed. These innovations are streamlining diagnostic processes, enabling earlier detection, and facilitating better patient outcomes through more precise, individualized treatment approaches.

What Are the Emerging Trends and Challenges in Cancer Diagnostics?

Several key trends are currently shaping the cancer diagnostics market, each influencing how cancer is detected and managed. A major trend is the increasing demand for non-invasive diagnostics, such as liquid biopsy and advanced imaging techniques, which minimize patient discomfort and reduce the time needed to obtain results. This shift towards minimally invasive methods is gaining traction as patients and healthcare providers alike look for safer and more convenient options. Another trend is the growing emphasis on early detection, driven by rising awareness of cancer screening's life-saving potential. Screening programs for cancers such as breast, colorectal, and lung have expanded, leading to increased demand for diagnostic tools that can catch cancer at its earliest stages. However, the field faces several challenges as well. The complexity and cost of advanced diagnostic technologies can pose barriers to widespread adoption, particularly in low- and middle-income regions. Moreover, the sheer volume of data generated by genomic testing and imaging requires sophisticated data management and analysis systems, posing a challenge for healthcare providers in terms of integration and interpretation. Despite these challenges, the trend towards personalized medicine and early detection continues to propel innovation in cancer diagnostics.

What Factors Are Fueling the Expansion of the Cancer Diagnostics Market?

The growth in the cancer diagnostics market is driven by several factors, primarily advances in technology, rising cancer prevalence, and the increasing emphasis on early detection and personalized treatment. One of the key growth drivers is the surge in demand for molecular diagnostics, particularly next-generation sequencing (NGS) and liquid biopsy technologies, which provide more accurate and less invasive options for detecting cancer. The growing adoption of personalized medicine, where treatment plans are tailored to the individual’s genetic profile, has also spurred demand for diagnostic tools that can identify specific biomarkers and mutations. Additionally, the rising global incidence of cancer, driven by factors such as aging populations and lifestyle-related risk factors, is increasing the need for diagnostic solutions that can detect cancer early and improve patient outcomes. Government initiatives and healthcare policies promoting regular cancer screenings have also fueled the demand for diagnostic tests, particularly in developed markets. Another significant factor driving market growth is the integration of artificial intelligence and machine learning into diagnostic imaging and data analysis, which enhances the accuracy and speed of cancer detection. These factors, combined with the continued expansion of diagnostic capabilities into emerging markets, are expected to sustain the rapid growth of the cancer diagnostics industry in the years to come.

SCOPE OF STUDY:

The report analyzes the Cancer Diagnostics market by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Instruments Offering, Consumables Offering, Services Offering); Test Type (Biopsy Test Type, Other Test Types); Application (Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application, Other Applications); End-Use (Hospitals End-Use, Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Applied Image Inc.
  • AstraZeneca PLC
  • AutoGenomics, Inc.
  • Becton, Dickinson Company
  • Bayer AG
  • BioCorRx, Inc.
  • bioMeriux SA
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Pfizer, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 47 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cancer Globally Spurs Growth in Demand for Cancer Diagnostics
    • Technological Advancements in Genomics Throw the Spotlight on Precision Cancer Diagnostics
    • Growth in Personalized Medicine Expands Addressable Market Opportunity for Advanced Diagnostic Tools
    • Increasing Focus on Early Detection Propels Adoption of Non-Invasive Cancer Diagnostic Techniques
    • Growing Use of Liquid Biopsy Accelerates Demand for Minimal Invasive Cancer Diagnostic Methods
    • Expanding Applications of Biomarker Testing Sustain Growth in Cancer Diagnostics
    • Innovations in Imaging and Screening Generate New Opportunities for Early Cancer Detection
    • Shift toward Point-of-Care Diagnostics Strengthens Demand for Portable Cancer Diagnostic Tools
    • Growth in Molecular Diagnostics Expands Market Potential for Targeted Cancer Screening
    • Growing Use of Next-Generation Sequencing Accelerates Precision Cancer Diagnostics Adoption
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 2: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 3: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 4: World Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Instruments Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Instruments Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Consumables Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Consumables Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Consumables Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Services Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Services Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Services Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Biopsy Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Biopsy Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Biopsy Test Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Breast Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Colorectal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Colorectal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Colorectal Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Cervical Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Cervical Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Cervical Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Lung Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Prostate Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Prostate Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Prostate Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Skin Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Skin Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Skin Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 41: World Recent Past, Current & Future Analysis for Blood Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 42: World Historic Review for Blood Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: World 13-Year Perspective for Blood Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 44: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 45: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: World 13-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 47: World Recent Past, Current & Future Analysis for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 48: World Historic Review for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: World 13-Year Perspective for Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 50: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 51: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: USA Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: USA 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 56: USA Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: USA Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: USA 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 59: USA Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: USA Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: USA 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 62: USA Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: USA Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: USA 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Canada Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: Canada 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Canada Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Canada 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Canada Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Canada 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Canada Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Canada 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • JAPAN
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Japan Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Japan 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Japan Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: Japan 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Japan Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: Japan 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Japan Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: Japan 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • CHINA
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: China Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: China 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 92: China Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: China Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: China 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 95: China Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: China Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: China 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 98: China Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: China Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: China 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • EUROPE
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Europe Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Europe 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 105: Europe Historic Review for Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Europe 13-Year Perspective for Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Europe Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Europe 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Europe Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: Europe 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: Europe Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: Europe 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • FRANCE
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 116: France Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: France Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: France 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 119: France Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: France Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: France 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 122: France Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: France Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: France 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 125: France Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: France Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: France 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • GERMANY
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Germany Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Germany 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Germany Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Germany 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Germany Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Germany 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Germany Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Germany 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Italy Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Italy 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Italy Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Italy 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Italy Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Italy 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Italy Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Italy 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 152: UK Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: UK Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: UK 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 155: UK Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: UK Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: UK 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 158: UK Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: UK Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: UK 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 161: UK Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: UK Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: UK 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Spain Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Spain 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Spain Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Spain 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Spain Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Spain 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Spain Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Spain 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Russia Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: Russia 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Russia Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Russia 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Russia Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Russia 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Russia Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Russia 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Europe 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Rest of Europe 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Rest of Europe 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Rest of Europe 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Asia-Pacific 13-Year Perspective for Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Asia-Pacific 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Asia-Pacific 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Asia-Pacific 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Asia-Pacific 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Australia Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Australia 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Australia Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Australia 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Australia Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Australia 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Australia Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Australia 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • INDIA
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 227: India Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: India Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: India 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 230: India Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: India Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: India 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 233: India Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: India Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: India 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 236: India Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: India Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: India 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: South Korea Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: South Korea 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: South Korea Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: South Korea 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: South Korea Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: South Korea 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: South Korea Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: South Korea 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Latin America Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Latin America 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 267: Latin America Historic Review for Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Latin America 13-Year Perspective for Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Latin America Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Latin America 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Latin America Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Latin America 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Latin America Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Latin America 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Argentina Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Argentina 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Argentina Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: Argentina 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: Argentina Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: Argentina 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Argentina Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: Argentina 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Brazil Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: Brazil 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Brazil Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Brazil 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Brazil Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Brazil 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Brazil Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Brazil 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Mexico Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Mexico 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Mexico Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: Mexico 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Mexico Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 310: Mexico 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 312: Mexico Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 313: Mexico 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 316: Rest of Latin America 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 319: Rest of Latin America 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 322: Rest of Latin America 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 325: Rest of Latin America 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 327: Middle East Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 328: Middle East 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 330: Middle East Historic Review for Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 331: Middle East 13-Year Perspective for Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 333: Middle East Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 334: Middle East 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 336: Middle East Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 337: Middle East 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 339: Middle East Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 340: Middle East 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 342: Iran Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 343: Iran 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 345: Iran Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 346: Iran 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 348: Iran Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 349: Iran 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 351: Iran Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 352: Iran 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 354: Israel Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 355: Israel 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 357: Israel Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 358: Israel 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 360: Israel Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 361: Israel 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 363: Israel Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 364: Israel 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 367: Saudi Arabia 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 370: Saudi Arabia 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 373: Saudi Arabia 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 376: Saudi Arabia 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 378: UAE Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 379: UAE 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 381: UAE Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 382: UAE 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 384: UAE Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 385: UAE 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 387: UAE Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 388: UAE 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 391: Rest of Middle East 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 394: Rest of Middle East 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 397: Rest of Middle East 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 400: Rest of Middle East 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • AFRICA
    • Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 402: Africa Historic Review for Cancer Diagnostics by Application - Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 403: Africa 13-Year Perspective for Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Colorectal Cancer Application, Cervical Cancer Application, Lung Cancer Application, Prostate Cancer Application, Skin Cancer Application, Blood Cancer Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 405: Africa Historic Review for Cancer Diagnostics by Offering - Instruments Offering, Consumables Offering and Services Offering Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 406: Africa 13-Year Perspective for Cancer Diagnostics by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Services Offering for the Years 2020, 2026 & 2032
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 408: Africa Historic Review for Cancer Diagnostics by Test Type - Biopsy Test Type and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 409: Africa 13-Year Perspective for Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Biopsy Test Type and Other Test Types for the Years 2020, 2026 & 2032
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 411: Africa Historic Review for Cancer Diagnostics by End-Use - Hospitals End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 412: Africa 13-Year Perspective for Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기